Comentis is engaged in the development of small-molecule drugs designed to either inhibit or enhance angiogenesis, based on the discovery of a new endothelial cell angiogenesis pathway, known as the nAChR pathway. Comentis’s lead products are being developed as oral compounds to treat diseases caused by enhanced angiogenesis, such as cancer and age-related macular degeneration (AMD), as well as topical formulations to treat diseases caused by impaired angiogenesis, such as non-healing wounds. Athenagen plans to introduce two drug candidates into the clinic in 2006: ATG001, an oral anti-angiogenesis compound, for exudative age-related macular degeneration and ATG002, a topical pro-angiogenesis compound, for diabetic foot ulcers.


Date Type Amount Investors Valuation
06/05/08 Series D 20M Astellas Venture Management, Clarus Ventures, Life Science Angels, Sanderling, Wellington Management Unknown


Ken Kengatharan (VP pre-clinical research and development)

John Hey (VP Non-clinical Development)

Carl Grove (VP Development Operations & Regulatory Affairs)

Griffin Murray (VP Corporate Finance)

John Cooke (VP Scientific Officer)

View more details about all 14 people at CoMentis